top of page

Search Results

Search results for "Structure Therapeutics"

Results found for "Structure Therapeutics"

  • Harnessing Deep Mutational Scanning for Enhanced Drug Discovery

    This data can guide the modification of the chemical structure of the lead compounds to improve potency development of more personalised therapies tailored to the genetic makeup of individual patients, enhancing therapeutic that can drive the early stages of target and lead identification, combat drug resistance, and refine therapeutic

  • Ever Wondered How Drugs Are Discovered?

    How do molecules make the leap from laboratory concept to therapeutic reality? miss the forest for the trees The critical importance of translation —turning lab data into meaningful therapeutic

  • đź“° GPCR Weekly News, June 17 to 23, 2024

    and triterpenes isolated from Cryptostegia grandiflora against Candida auris FKBP12 Development and therapeutic opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision Structural and Molecular Insights into GPCR Function Structure and dynamics of the pyroglutamylated RF-amide peptide

  • How GPCR Spatial Signaling Sparked a Scientific Journey

    For innovators building tools, platforms, or therapeutics, these origin moments are where tomorrow’s receptors control localised signaling, how disease hijacks these systems, and how to target them for therapeutic Her work sits at the intersection of fundamental biology and therapeutic strategy. Knowing where  signals occur could unlock new therapeutic strategies, better efficacy, and fewer side

  • The Real Cost of Strategic Overload in Biotech

    It is the structural alignment between capital, milestones, and narrative. What begins as intelligent expansion gradually becomes structural strain. It is solved by structural decisions. Before the next biotech fundraising cycle, leadership teams should pressure test their structure with It is a diluted commitment. 👉 Biotech fundraising reflects the structure of your strategy long before

  • Transmembrane domains of GPCR dimers – a novel hot spot for drug discovery

    GPCR dimers are therefore emerging drug targets in different therapeutic areas including depression, Structural insights into metabotropic glutamate receptors have shown that the dimerization interface peptide derived from TM5/TM6 of the cannabinoid CB1 receptor (CB1R) which has been shown to alter the structure

  • Profiling Immune Cell and Platelet Transcriptomes

    signaling, influencing a wide array of physiological processes and serving as critical targets for therapeutic significant findings that enhance our understanding of GPCRs' roles in immune function and potential therapeutic macrophages suggest that these GPCRs could be targeted to modulate inflammatory responses, offering potential therapeutic the field continues to evolve, the insights gained from this research will be instrumental in shaping therapeutic

  • Understanding Orthosteric Binding: The Key to Drug Action

    This foundational knowledge guides researchers in the development of new therapeutics. It can inform decisions in drug design, improving therapeutic outcomes and reducing unwanted side effects This understanding can enhance your appreciation for drug development and therapeutic action.

  • Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization

    Fresh selectivity datasets on openMe; Novo’s obesity dominance faces new challengers; integrating AI + structure Separate effect size from time:  Use allosteric modulators to expand therapeutic index and reduce overdose Why It Matters In the CNS, where receptor localization and real-time signaling shape therapeutic outcomes

  • From Switches to Microcircuits: GPCR Biased Signaling and the Future of Drug Discovery

    Ligands designed to activate therapeutically beneficial pathways, while avoiding those associated with The therapeutic logic is sound: if signaling pathways are separable, they are potentially selectable. Family C), adhesion GPCRs, and Frizzled receptors (Family VI) have all attracted growing interest as new therapeutic both been implicated in COVID-19 pathophysiology — and represent active targets for receptor-directed therapeutic provides the needed mechanistic depth to define the functional selectivity  that may ultimately determine therapeutic

  • Dr. GPCR and Eurofins Discovery Join Forces to Advance GPCR Drug Discovery

    portfolio of more than 2,750 assays, and one of the broadest ranges of GPCR targets in the industry, across therapeutic sharing our science, our services, and our team's expertise with researchers advancing GPCR-targeted therapeutics

  • đź“° GPCR Weekly News, November 20 to 26, 2023

    intact Drosophila melanogaster Reviews, GPCRs, and more Catecholamine Derivatives: Natural Occurrence, Structural and Molecular Insights into GPCR Function Structural and signaling mechanisms of TAAR1 enabled preferential agonist design Proteome-wide structural analysis quantifies structural conservation across distant species from Kisqali®, iptacopan and Scemblix® at SABCS and ASH Research reveals pro-phagocytic function and structural Innovative AI-Driven Drug Design at BRIC AI 2023 Workshop Salipro Biotech AB Celebrates Milestones in CryoEM Structures

  • GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions

    GPCR ligands pharmacology The impact of a ligand on a receptor's structure and biophysical attributes theoretically offer several advantages compared to orthosteric ligands when considered as potential therapeutic other GPCR-regulated systems such as free fatty acid receptors (FFARs), now regarded as targets for therapeutic

  • Inside Out: Mapping GPCRs from Membrane Codes to Market Moves

    Selection  – Master GPCR behavior beyond second messengers   Build sharper strategies for GPCR-targeted therapeutics receptor biology—and how they’re being used to de-orphanize GPCRs, explore autoantibodies, and uncover new therapeutic

  • Applications of Fluorescent Probes in Confocal Imaging of GPCRs: From Live to Fixed Cells

    ligands , where a fluorescent tag is attached to a pharmacophore , the receptor also keeps its original structure On the other hand, in fixed cells studies, it facilitates the structural context necessary to map receptor Microscopy and spectroscopy approaches to study GPCR structure and function.

  • The Hidden Operating Cadence That’s Actually Driving Your Biotech

    BD conversations move optimistically but without a structured readiness signal behind them. When teams adopt structured decision cycles, consistent narrative checkpoints, and predictable timeline The shift is simple: 👉 From reactivity → to rhythmic leadership 👉 From heroic effort → to structured

  • Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal

    Screening technologies, structure-informed design, and AI are accelerating target selection. Antibodies, Bias, and the Expanding Modality Landscape Antibody therapeutics are now entering spaces

  • Scientific Isolation: The Real Reason Early Biotechs Lose Traction

    Clear structure gives your science the visibility and consistency that traction is built on. Alignment, structure, traction, visibility: these are the forces that pull a biotech out of scientific It’s about restoring the connection  between science, strategy, and the outside world. 👉 Here’s a structure

  • Unveiling GPCR Priming: The Hidden Synergy in Cellular Signalling

    implications for drug development, as targeting these non-cognate interactions could lead to novel therapeutic Hilger, D., et al., Structural insights into differences in G protein activation by family A and family

  • Understanding Enzyme Inhibition In GPCR Discovery Programs

    When “inhibition” becomes activation—and how that insight fuels next-gen therapeutic design. It’s built for scientists and teams who want fewer tabs and faster decisions—one scroll that blends structure

  • Conservation of Allosteric Ligand Binding Sites in G-Protein Coupled Receptors

    November 2022 "Despite the growing number of G protein-coupled receptor (GPCR) structures, only 39 structures These structures have been studied by protein mapping using the FTMap server, which determines the clustering method has found druggable sites overlapping with the cocrystallized allosteric ligands in 21 GPCR structures We then mapped the 394 GPCR X-ray structures available at the time of the analysis (September 2020). Results show that for each of the 21 structures with bound ligands there exist many other GPCRs that

  • đź“° GPCR Weekly News

    GPCRs in Neuroscience CGRP physiology, pharmacology, and therapeutic targets: Migraine and beyond. Structural and Molecular Insights into GPCR Function Computational investigation of functional water Cryo-EM structure of G-protein-coupled receptor GPR17 in complex with inhibitory G protein.

  • Overview of adhesion GPCRs self-activation

    Structurally they characterize by a long extracellular region of adhesion-like domains which modulate As if its structure were not already complex enough, during their synthesis in the endoplasmic reticulum -Q., et al., Structural basis for the tethered peptide activation of adhesion GPCRs. Qu, X., et al., Structural basis of tethered agonism of the adhesion GPCRs ADGRD1 and ADGRF1. Structural insights into adhesion GPCR ADGRL3 activation and Gq, Gs, Gi, and G12 coupling.

  • The One Reason Why Biotech Startups Fail More Often Than They Should

    It is a structural one.   The danger is letting complexity grow without a structure that contains it.   When decisions follow a visible structure, complexity becomes manageable rather than overwhelming. They fail when complexity grows without structure and clarity.  

  • Comparative studies of AlphaFold, RoseTTAFold and Modeller: a case study involving the use of...

    We collected the experimentally determined structures of 73 GPCRs from the Protein Data Bank. The predicted models were then aligned with the experimentally solved structures and evaluated by the If only looking at each program's top-scored structure, Modeller had the smallest average modeling RMSD than AlphaFold's 5.53 Ă… and RoseTTAFold's 6.28 Ă…, probably since Modeller already included many known structures the NN-based methods were primarily due to the differences in loop prediction compared to the crystal structures

  • GPCR Selectivity Beyond the Receptor

    Biased signaling frameworks centered on receptor conformations have a structural limitation when selectivity This session with Kenneth Jacobson and Matteo Pavan examines the structural determinants that make selective HEK293 systems are powerful tools for scalable pharmacological screening, but they have a structural

  • đź“° GPCR Weekly Buzz: Exciting Schedule Shifts for Principles of Pharmacology I & II | August 12-18, 2024

    Measuring G protein activation by spectrally resolved imaging fluorescence fluctuation spectroscopy Structural and Molecular Insights into GPCR Function Monitoring GPCR conformation with GFP-inspired dyes Structural basis for the ligand recognition and G protein subtype selectivity of kisspeptin receptor Structural analysis of the human C5a-C5aR1 complex using cryo-electron microscopy Structural analysis of the human

  • Beyond Clearance: The Strategic Power of Irreversible Drug Binding

    When a drug outlives its exposure , toxic interactions can be just as persistent as therapeutic ones. When these drugs hit structured tissues (like solid tumors), they can get trapped at the periphery, leaving

  • Drug Discovery Pharmacology Principles That Turn Assays Into Real Medicines

    Kenakin highlights that therapeutic efficacy depends on the period during which a drug is actively engaged mechanistic insight into receptor signaling quantitative frameworks for decision making Chemists contribute: structural

  • đź“° GPCR Weekly News, October 16 to 22, 2023

    bioluminescence resonance energy transfer to quantitate cell-surface expression of membrane proteins Structural potential use of Opn5 and its homologs Industry News The Leading GPCR Company in Immuno-Oncology, Domain Therapeutics

bottom of page